

Medicare Part D Formularies (MA-PD only, excluding SNP, for 30-day supply)
(Table 3)

Report on CMS formulary files (January 2025 and January 2024). All calculations are percentages of formularies, except for co-pay, which is in dollars, and coinsurance, which is a percentage of drug price.

Drugs selected for Medicare Drug Price Negotiation in 2026

Non-specialty	2025	2024	2025	2024	2025	2024	2025	2024
	On	Change vs. 2024	Without	Change vs. 2024	Tier 3 or	Change vs. 2024	Average	Change vs. 2024
Generic (brand name)	formulary		prior author-ization		lower		co-pay	
apixaban (Eliquis)		100	0	100	0	98	2	\$ 43
dapagliflozin propanediol (Farxiga)		96	3	100	0	86	1	\$ 37
empagliflozin (Jardiance)		100	0	100	0	100	1	\$ 37
insulin aspart (Fiasp/Novolog)		66	6	100	0	98	2	\$ 37
rivaroxaban (Xarelto)		100	0	100	0	98	1	\$ 44
sacubitril/valsartan (Entresto)		100	0	100	0	100	1	\$ 42
sitagliptin phosphate (Januvia)		97	3	100	0	100	2	\$ 37

Specialty	On	Change vs. 2024	Without	Change vs. 2024	Tier 3 or	Change vs. 2024	Average	Change vs. 2024
	formulary		prior author-ization		lower		coinsurance	
etanercept (Enbrel)		86	-14	2	0	1	0	30
ibrutinib (Imbruvica)		100	0	2	0	1	0	30
ustekinumab (Stelara)		100	0	0	0	1	0	30

Drugs selected for Medicare Drug Price Negotiation in 2027

Non-specialty	2025	2024	2025	2024	2025	2024	2025	2024
	On	Change vs. 2024	Without	Change vs. 2024	Tier 3 or	Change vs. 2024	Average	Change vs. 2024
Generic (brand name)	formulary		prior author-ization		lower		co-pay	
fluticasone/umeclidin/vilanter (Trelegy Ellipta)		98	0	100	0	100	0	\$ 42
fluticasone/vilanterol (Breo Ellipta)		98	0	100	0	100	0	\$ 42
linaclotide (Linzess)		100	0	100	1	96	30	\$ 46
linagliptin (Tradjenta)		95	-3	100	0	100	1	\$ 38
semaglutide (Ozempic)		98	0	0	-16	96	-3	\$ 42
sitagliptin phos/metformin HCl (Janumet)		97	3	100	0	100	2	\$ 37

DLA Piper analysis of CMS formulary files MA-PD

Specialty	On formulary	Change vs. 2024	Without prior author- ization	Change vs. 2024	Tier 3 or lower	Change vs. 2024	Average coinsurance	Change vs. 2024
acalabrutinib (Calquence)	100	0	2	0	1	0	30	-1
apremilast (Otezla)	63	-37	0	0	1	0	31	0
cariprazine HCl (Vraylar)	100	0	73	7	1	-1	31	-4
deutetrabenazine (Austedo)	90	4	3	0	1	0	30	-2
enzalutamide (Xtandi)	100	0	2	-1	1	0	30	-1
nintedanib Esylate (Ofev)	100	0	2	0	1	0	30	-1
palbociclib (Ibrance)	100	0	2	0	1	0	30	-1
pomalidomide (Pomalyst)	100	0	2	0	1	0	30	-1
rifaximin (Xifaxan)	100	0	7	-6	10	0	32	0